In this time of crisis, the life science industry has demonstrated remarkable speed, innovation and resilience. In this episode of the After the Curve podcast, our life sciences partners join us to discuss the most promising areas of drug discovery and device development that are emerging from the pandemic and the outlook for the industry in a post-COVID-19 world. McDermott’s Chief Marketing Officer, Leslie Tullio, is joined by Stephen Bernstein and Kristian Werling to discuss key topics impacting the life sciences industry today, including:

• The reasons behind the immunity of life sciences to slowed investments
• Why more investors are focusing their equity in healthcare and life sciences
• Promising areas of drug discovery and device development emerging from the pandemic
• Critical considerations for life science companies regarding rapid regulatory changes
• Tactics for moving developments forward at an increased speed
• The importance of Collaborative Transformation to the life sciences industry

COVID-19 has demanded a rapid shift in the world of telehealth and digital health, resulting in a global embracing of a telehealth and digital health system that is not yet fully developed. On this episode of the McDermott Health podcast, our digital health partners have joined to discuss the future of telehealth and use of digital tools to speed up care delivery and to improve outcomes in the wake of COVID-19, as well as the vital role of data readiness in reshaping the healthcare system. McDermott’s Chief Marketing Officer Leslie Tullio is joined by partners Stephen Bernstein and Lisa Mazur to examine current trends and potential changes to both telehealth as well as the broader digital health landscape, including:

• The most impactful regulatory telehealth changes that have resulted from COVID-19
• A look beyond telehealth to a paradigm shift in the broader digital health landscape
• The impact that a more refined data exchange pathway could have on treatment during the next wave of COVID-19 or future pandemics
• Meaningful collaborations that are currently happening in the digital health space
• A look at innovations that are emerging from the demands of post-COVID-19 healthcare
• Legal and regulatory compliance steps that still need to be taken to allow these telehealth programs to continue in the future

Public hospital mergers and acquisitions (M&A) presents a host of complex business and legal issues for buyers, sellers, employees, local governments and numerous other stakeholders. In the second episode of our three-part Collaborative Transformation podcast series on public hospital M&A, we are joined by Rex Burgdorfer, managing director at Juniper Advisory to discuss:

• Key issues that hospital boards, senior leaders and partners must address to secure transaction approval
• Strategies for identifying and educating stakeholders about the proposed transaction, including competitive benefits and tax and political implications
• Choosing a deal structure that will work for all parties and anticipating complications that may arise with alternative deal structures
• Effectively communicating with employees to keep hospital operations running smoothly during the transaction approval process.

Listen now.

Public hospitals have a uniquely open relationship to the communities they serve, which invites a level of transparency as they consider potential mergers and acquisitions. So what kind of M&A deal activity options are out there for public hospitals dealing with financial pressures, and how can parties navigate regulatory, financial and public opinion to get the deal done? In this episode of Collaborative Transformation podcast series, Rex Burgdorfer, managing director at Juniper Advisory, joins McDermott partner Megan Rooney to discuss:

• The major trends driving public hospital M&A
• How M&A can strengthen hospitals financially and the regulatory and external challenges contributing to financial pressures
• Unique regulatory and financial challenges faced by public hospitals
• Benefits of privatization in the hospital industry
• The role public sentiment can play in public hospital transactions

An increasingly critical duty for boards of directors relates to the supervision, compensation and retention of the senior executive leadership team. On this episode, the first in a two-part series, Michael Peregrine welcomes Tim Cotter, managing director of SullivanCotter, and Ralph DeJong, partner at McDermott Will and Emery, for a discussion on the latest trends and developments impacting the executive compensation committee’s decision-making process.

You will learn:

• Where executive compensation is trending in 2020
• Increasing expectations of engagement by members of the executive compensation committee
• How coordination between the executive compensation committee and other board-level committees is increasing
• Potential effects of political, reputational and other environmental factors on executive compensation decisions
• Impact of today’s high CEO turnover on board oversight standards and talent retention practices in healthcare